Moiseev, S V <br/><br/>
[Severe adverse events from treatment with genetically engineered biological agents in patients with rheumatic diseases].  [electronic resource] 

 -  Terapevticheskii arkhiv  2013 
 - 37-43 p.  digital 
<br/><br/> Publication Type: Controlled Clinical Trial; English Abstract; Journal Article 
<br/><br/><label>ISSN: </label>0040-3660 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis--drug therapy<br/>Antibodies, Monoclonal--adverse effects<br/>Antibodies, Monoclonal, Murine-Derived--adverse effects<br/>Arthritis, Rheumatoid--drug therapy<br/>Female<br/>Genetic Engineering<br/>Humans<br/>Immunologic Factors--adverse effects<br/>Infliximab<br/>Lupus Erythematosus, Systemic--drug therapy<br/>Male<br/>Remission Induction--methods<br/>Rheumatic Diseases--drug therapy<br/>Rituximab<br/>Severity of Illness Index<br/>Treatment Outcome